Clinical trial
A Prospective Phase II Clinical Study to Evaluate the Efficacy and Safety of Hypofractionated Radiotherapy Combined With Granulocyte-Macrophage Colony-Stimulating Factor, Pomalidomide and Glofitamab in Patients With Newly Diagnosed Primary Central Nervous System Diffuse Large B-Cell Lymphoma
NCT07749365 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Xiamen University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective Phase II Clinical Study to Evaluate the Efficacy and Safety of Hypofractionated Radiotherapy Combined With Granulocyte-Macrophage Colony-Stimulating Factor, Pomalidomide and Glofitamab in Patients With Newly Diagnosed Primary Central Nervous System Diffuse Large B-Cell Lymphoma
- Lead sponsor
- The First Affiliated Hospital of Xiamen University
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- July 25, 2026
- Completion date
- December 31, 2029
- Enrollment
- 53 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
dlbcl - diffuse large b cell lymphoma, pcnsl (primary cns lymphoma)